From: Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
Galantamine plasma concentration after 2 months of treatment (n= 47) | Change in MMSE score after 2 monthsa | Galantamine plasma concentration after 6 months of treatment (n= 41) | Change in MMSE score after 6 monthsa | Change in ADAS-cog score after 6 monthsa | Change in IADL score after 6 monthsa |
---|---|---|---|---|---|
Quartile 1, < 0.143 μmol/L | 0.42 (-1.17, 2.01) | Quartile 1, < 0.152 μmol/L | 1.50 (-0.16, 3.16) | -1.90 (-5.51, 1.71) | -0.20 (-1.36, 0.96) |
Quartile 2, 0.143 to 0.205 μmol/L | 0.25 (-1.11, 1.61) | Quartile 2, 0.152 to 0.225 μmol/L | -0.36 (-1.33, 0.60) | 0.36 (-1.12, 1.84) | -2.56 (-4.73, -0.38) |
Quartile 3, 0.205 to 0.279 μmol/L | 0.67 (-0.58, 1.92) | Quartile 3, 0.225 to 0.267 μmol/L | -0.60 (-2.19, 0.99) | -0.22 (-4.34, 3.90) | -2.89 (-6.36, 0.58) |
Quartile 4, > 0.279 μmol/L | -0.36 (-1.81, 1.09) | Quartile 4, > 0.267 μmol/L | 0.50 (-1.74, 2.74) | -0.20 (-2.25, 1.85) | 0.00 (-1.15, 1.15) |